157 related articles for article (PubMed ID: 38254758)
21. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials.
Ducoulombier A; Cousin S; Kotecki N; Penel N
Crit Rev Oncol Hematol; 2016 Feb; 98():73-80. PubMed ID: 26555460
[TBL] [Abstract][Full Text] [Related]
23. A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma.
Liu YC; Su CW; Ko PS; Lee RC; Liu CJ; Huang YH; Gau JP; Liu JH
Asia Pac J Clin Oncol; 2022 Feb; 18(1):19-27. PubMed ID: 32964588
[TBL] [Abstract][Full Text] [Related]
24. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
Hensley ML
Curr Opin Oncol; 2010 Jul; 22(4):356-61. PubMed ID: 20520541
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy and radiotherapy for advanced pancreatic cancer.
Chin V; Nagrial A; Sjoquist K; O'Connor CA; Chantrill L; Biankin AV; Scholten RJ; Yip D
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011044. PubMed ID: 29557103
[TBL] [Abstract][Full Text] [Related]
26. A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.
D'Adamo DR; Dickson MA; Keohan ML; Carvajal RD; Hensley ML; Hirst CM; Ezeoke MO; Ahn L; Qin LX; Antonescu CR; Lefkowitz RA; Maki RG; Schwartz GK; Tap WD
Oncologist; 2019 Jun; 24(6):857-863. PubMed ID: 30126857
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Jones RL; Demetri GD; Schuetze SM; Milhem M; Elias A; Van Tine BA; Hamm J; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Patel S; von Mehren M
Ann Oncol; 2018 Sep; 29(9):1995-2002. PubMed ID: 30084934
[TBL] [Abstract][Full Text] [Related]
28. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Schlick K; Gantschnigg A; Seymer A; Huemer F; Greil R; Weiss L
Cancer Med; 2023 Aug; 12(16):16997-17004. PubMed ID: 37537780
[TBL] [Abstract][Full Text] [Related]
29. A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study.
Martínez-Trufero J; De Sande-González LM; Luna P; Martin-Broto J; Álvarez R; Marquina G; Diaz-Beveridge R; Poveda A; Cano JM; Cruz-Jurado J; López Pousa A; Vaz Salgado MA; Valverde-Morales CM; Sevilla I; Martínez-García J; Rubio-Casadevall J; De Juan A; Carrasco JA; Moura DS; Gurruchaga-Sotes I; Gutiérrez A
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672857
[TBL] [Abstract][Full Text] [Related]
30. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
31. A meta-analysis of randomized controlled trials that compare standard doxorubicin with other first-line chemotherapies for advanced/metastatic soft tissue sarcomas.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
PLoS One; 2019; 14(1):e0210671. PubMed ID: 30629708
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
Ferraresi V; Ciccarese M; Cercato MC; Nuzzo C; Zeuli M; Di Filippo F; Giannarelli D; Cognetti F
Cancer Chemother Pharmacol; 2008 Dec; 63(1):149-55. PubMed ID: 18351342
[TBL] [Abstract][Full Text] [Related]
33. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity.
Vlenterie M; Litière S; Rizzo E; Marréaud S; Judson I; Gelderblom H; Le Cesne A; Wardelmann E; Messiou C; Gronchi A; van der Graaf WT
Eur J Cancer; 2016 May; 58():62-72. PubMed ID: 26968015
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas.
Sonnenblick A; Eleyan F; Peretz T; Ospovat I; Merimsky O; Sella T; Peylan-Ramu N; Katz D
Mol Clin Oncol; 2015 Jul; 3(4):829-832. PubMed ID: 26171190
[TBL] [Abstract][Full Text] [Related]
36. A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients' Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece.
Kokkali S; Boukovinas I; Samantas E; Papakotoulas P; Athanasiadis I; Andreadis C; Makrantonakis P; Samelis G; Timotheadou E; Vassilopoulos G; Papadimitriou C; Tzanninis D; Ardavanis A; Kotsantis I; Karvounis-Marolachakis K; Theodoropoulou T; Psyrri A
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454787
[TBL] [Abstract][Full Text] [Related]
37. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
38. SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Digklia A; Kollár A; Dietrich D; Kronig MN; Britschgi C; Rordorf T; Joerger M; Krasniqi F; Metaxas Y; Colombo I; Ribi K; Rothermundt C
Eur J Cancer; 2024 Jan; 197():113470. PubMed ID: 38096656
[TBL] [Abstract][Full Text] [Related]
39. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
[TBL] [Abstract][Full Text] [Related]
40. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis.
Zhou K; Cao J; Lin H; Liang L; Shen Z; Wang L; Peng Z; Mei J
Front Oncol; 2022; 12():962173. PubMed ID: 36059629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]